Kovitz Investment Group Partners LLC Has $3.49 Million Stock Holdings in Sanofi $SNY

Key Points

• Kovitz Investment Group Partners LLC increased its stake in Sanofi by 294.4% during the first quarter, now holding 62,859 shares valued at approximately $3.48 million.
• During the most recent quarter, Sanofi reported earnings per share of $0.90, missing estimates by $0.06, while revenue decreased by 7.0% compared to the previous year.
• Several analysts upgraded Sanofi's stock ratings, with a majority assigning a "Buy" rating and an average target price of $62.00, reflecting a positive outlook on the stock's performance.

Kovitz Investment Group Partners LLC raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 294.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,859 shares of the company's stock after purchasing an additional 46,921 shares during the period. Kovitz Investment Group Partners LLC's holdings in Sanofi were worth $3,486,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after purchasing an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC raised its position in Sanofi by 130.5% during the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after purchasing an additional 5,794 shares in the last quarter. Ballentine Partners LLC raised its position in Sanofi by 68.7% during the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after purchasing an additional 10,617 shares in the last quarter. Sowell Financial Services LLC acquired a new position in Sanofi during the first quarter valued at approximately $328,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Sanofi by 66.2% during the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after buying an additional 2,476 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sanofi in a research note on Tuesday, August 5th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Sanofi currently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Trading Up 0.2%

Shares of NASDAQ:SNY traded up $0.08 during mid-day trading on Thursday, reaching $50.61. 1,491,271 shares of the company's stock were exchanged, compared to its average volume of 2,567,537. The firm has a market capitalization of $124.27 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.20 and a beta of 0.48. The business's fifty day moving average price is $48.59 and its 200-day moving average price is $51.76. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the business earned $1.73 EPS. Sanofi's quarterly revenue was down 7.0% on a year-over-year basis. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.